메뉴 건너뛰기




Volumn 9, Issue 2, 2010, Pages 154-169

Antiplatelet therapies for the treatment of cardiovascular disease

Author keywords

[No Author keywords available]

Indexed keywords

3A,4,4A,5,6,7,8,8A,9,9A DECAHYDRO N [4 [2 [5 (3 FLUOROPHENYL) 2 PYRIDYL]VINYL] 3 METHYL 1 OXO 3H BENZO[F]ISOBENZOFURAN 7 YL]CARBAMIC ACID ETHYL ESTER; ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450; E 5555; EFFIENT; ELINOGREL; G PROTEIN COUPLED RECEPTOR; INTEGRIN; INTEGRIN ALPHAIIB BETA3; INTEGRIN ALPHAIIB BETA3 ANTAGONIST; KISTOMIN; PADGEM PROTEIN; PHOSPHODIESTERASE INHIBITOR; PRASUGREL; PURINERGIC P2Y1 RECEPTOR; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RUC 1; SEROTONIN ANTAGONIST; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY TICK ANTICOAGULANT PEPTIDE FUSION PROTEIN; THROMBOXANE RECEPTOR BLOCKING AGENT; TICAGRELOR; TICLOPIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN;

EID: 75949128633     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2957     Document Type: Review
Times cited : (337)

References (152)
  • 1
    • 0037065502 scopus 로고    scopus 로고
    • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients
    • Antithrombotic Trialists' Collaboration
    • Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324,71-86 (2002).
    • (2002) BMJ , vol.324 , pp. 71-86
  • 2
    • 85013973898 scopus 로고    scopus 로고
    • Michelson, A. D. (ed.) 2nd edn (Elsevier/ Academic Press, San Diego
    • Michelson, A. D. (ed.) Platelets 2nd edn (Elsevier/ Academic Press, San Diego, 2007).
    • (2007) Platelets
  • 4
    • 2942546273 scopus 로고    scopus 로고
    • Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization
    • Furman, M. I. et al. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J. Am. Coll. Cardiol. 43, 2319-2325 (2004).
    • (2004) J. Am. Coll. Cardiol. , vol.43 , pp. 2319-2325
    • Furman, M.I.1
  • 5
    • 57349102283 scopus 로고    scopus 로고
    • 12 receptor-induced activation and kinocidin release
    • 12 receptor-induced activation and kinocidin release. Infect. Immun. 76, 5706-5713 (2008).
    • (2008) Infect. Immun. , vol.76 , pp. 5706-5713
    • Trier, D.A.1
  • 6
    • 38949178835 scopus 로고    scopus 로고
    • Angiogenesis is regulated by a novel mechanism: Pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released
    • Italiano, J. E. Jr et al. Angiogenesis is regulated by a novel mechanism: pro-and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111, 1227-1233 (2008).
    • (2008) Blood , vol.111 , pp. 1227-1233
    • Italiano Jr., J.E.1
  • 7
    • 75949129616 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) (Elsevier/Academic Press, San Diego
    • Nierodzik, M. L., Karpatkin, S. in Platelets 2nd edn (ed. Michelson, A. D.) 769-778 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 769-778
    • Nierodzik, M.L.1    Karpatkin, S.2
  • 8
    • 84884754706 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • White, J. G. in Platelets 2nd edn (ed. Michelson, A. D.) 45-73 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 45-73
    • White, J.G.1
  • 9
    • 84884795579 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Italiano, J. E. & Hartwig, J. H. in Platelets 2nd edn (ed. Michelson, A. D.) 23-44 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 23-44
    • Italiano, J.E.1    Hartwig, J.H.2    Levin, J.3
  • 10
    • 85013973898 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Levin, J. in Platelets 2nd edn (ed. Michelson, A. D.) 3-22 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 3-22
  • 12
    • 61849117080 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Hartwig, J. H. in Platelets 2nd edn (ed. Michelson, A. D.) 75-97 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 75-97
    • Hartwig, J.H.1
  • 13
    • 67649753929 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Rex, S. & Freedman, J. E. in Platelets 2nd edn (ed. Michelson, A. D.) 251-279 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 251-279
    • Rex, S.1    Freedman, J.E.2
  • 14
    • 84884808691 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Brass, L. F., Stalker, T. J., Zhu, L. & Woulfe, D. S. in Platelets 2nd edn (ed. Michelson, A. D.) 319-346 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 319-346
    • Brass, L.F.1    Stalker, T.J.2    Zhu, L.3    Woulfe, D.S.4
  • 16
    • 0029056992 scopus 로고
    • The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase
    • Loll, P. J., Picot, D. & Garavito, R. M. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Struct. Biol. 2, 637-643 (1995).
    • (1995) Nature Struct. Biol. , vol.2 , pp. 637-643
    • Loll, P.J.1    Picot, D.2    Garavito, R.M.3
  • 17
    • 46049108934 scopus 로고    scopus 로고
    • Antiplatelet drugs
    • American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
    • Patrono, C., Baigent, C., Hirsh, J. & Roth, G. Antiplatelet drugs. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133, S199-S233 (2008).
    • (2008) Chest , vol.133
    • Patrono, C.1    Baigent, C.2    Hirsh, J.3    Roth, G.4
  • 18
    • 56749160744 scopus 로고    scopus 로고
    • Lack of association between cyclooxygenase-1-dependent platelet function assays and adverse clinical outcomes in 700 consecutive aspirin-treated patients presenting for cardiac catheterization
    • Frelinger, A. L. et al. Lack of association between cyclooxygenase-1- dependent platelet function assays and adverse clinical outcomes in 700 consecutive aspirin-treated patients presenting for cardiac catheterization. J. Am. Coll. Cardiol. 51, A370 (2008).
    • (2008) J. Am. Coll. Cardiol. , vol.51
    • Frelinger, A.L.1
  • 20
    • 34447503098 scopus 로고    scopus 로고
    • Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis
    • Snoep, J. D., Hovens, M. M., Eikenboom, J. C., van der Bom, J. G. & Huisman, M. V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167, 1593-1599 (2007).
    • (2007) Arch. Intern. Med. , vol.167 , pp. 1593-1599
    • Snoep, J.D.1    Hovens, M.M.2    Eikenboom, J.C.3    Van Der Bom, J.G.4    Huisman, M.V.5
  • 21
    • 38949119325 scopus 로고    scopus 로고
    • Aspirin "resistance" and risk of cardiovascular morbidity: Systematic review and meta-analysis
    • Krasopoulos, G., Brister, S. J., Beattie, W. S. & Buchanan, M. R. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336, 195-203 (2008).
    • (2008) BMJ , vol.336 , pp. 195-203
    • Krasopoulos, G.1    Brister, S.J.2    Beattie, W.S.3    Buchanan, M.R.4
  • 22
    • 56749182302 scopus 로고    scopus 로고
    • Aspirin 'resistance': Role of pre-existent platelet reactivity and correlation between tests
    • Frelinger, A. L. et al. Aspirin 'resistance': role of pre-existent platelet reactivity and correlation between tests. J. Thromb.Haemost. 6, 2035-2044 (2008).
    • (2008) J. Thromb.Haemost. , vol.6 , pp. 2035-2044
    • Frelinger, A.L.1
  • 23
    • 84884759628 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Cattaneo, M. in Platelets 2nd edn (ed. Michelson, A. D.) 201-220 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 201-220
    • Cattaneo, M.1
  • 24
    • 84884782925 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Cattaneo, M. in Platelets 2nd edn (ed. Michelson, A. D.) 1127-1144 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 1127-1144
    • Cattaneo, M.1
  • 25
    • 40749148947 scopus 로고    scopus 로고
    • 12 antagonism: Promises and challenges. Arterioscler
    • 12 antagonism: promises and challenges. Arterioscler. Thromb. Vasc. Biol. 28, S33-S38 (2008).
    • (2008) Thromb. Vasc. Biol. , vol.28
    • Michelson, A.D.1
  • 26
    • 0034622539 scopus 로고    scopus 로고
    • Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: The clopidogrel aspirin stent international cooperative study (CLASSICS)
    • Bertrand, M. E., Rupprecht, H. J., Urban, P. & Gershlick, A. H. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 102, 624-629 (2000).
    • (2000) Circulation , vol.102 , pp. 624-629
    • Bertrand, M.E.1    Rupprecht, H.J.2    Urban, P.3    Gershlick, A.H.4
  • 27
    • 0035899289 scopus 로고    scopus 로고
    • Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation
    • Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
    • (2001) N. Engl. J. Med. , vol.345 , pp. 494-502
    • Yusuf, S.1
  • 28
    • 0035908781 scopus 로고    scopus 로고
    • Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study
    • Mehta, S. R. et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358, 527-533 (2001).
    • (2001) Lancet , vol.358 , pp. 527-533
    • Mehta, S.R.1
  • 29
    • 0037145863 scopus 로고    scopus 로고
    • Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
    • Steinhubl, S. R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002).
    • (2002) JAMA , vol.288 , pp. 2411-2420
    • Steinhubl, S.R.1
  • 30
    • 27644548513 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial
    • Chen, Z. M. et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366, 1607-1621 (2005).
    • (2005) Lancet , vol.366 , pp. 1607-1621
    • Chen, Z.M.1
  • 31
    • 20144373281 scopus 로고    scopus 로고
    • Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
    • Sabatine, M. S. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352, 1179-1189 (2005).
    • (2005) N. Engl. J. Med. , vol.352 , pp. 1179-1189
    • Sabatine, M.S.1
  • 32
    • 33645861080 scopus 로고    scopus 로고
    • Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    • Bhatt, D. L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354,1706-1717 (2006).
    • (2006) N. Engl. J. Med. , vol.354 , pp. 1706-1717
    • Bhatt, D.L.1
  • 33
    • 34548809256 scopus 로고    scopus 로고
    • An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
    • Wang, T. H. et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur. Heart J. 28, 2200-2207 (2007).
    • (2007) Eur. Heart J. , vol.28 , pp. 2200-2207
    • Wang, T.H.1
  • 34
    • 34447576539 scopus 로고    scopus 로고
    • Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
    • Snoep, J. D. et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154, 221-231 (2007).
    • (2007) Am. Heart J. , vol.154 , pp. 221-231
    • Snoep, J.D.1
  • 35
    • 8344221349 scopus 로고    scopus 로고
    • Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
    • Matetzky, S. et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171-3175 (2004).
    • (2004) Circulation , vol.109 , pp. 3171-3175
    • Matetzky, S.1
  • 36
    • 27644465874 scopus 로고    scopus 로고
    • Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study
    • Gurbel, P. A. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis. Results of the CREST study. J. Am. Coll. Cardiol. 46, 1827-1832 (2005).
    • (2005) J. Am. Coll. Cardiol. , vol.46 , pp. 1827-1832
    • Gurbel, P.A.1
  • 37
    • 33645982865 scopus 로고    scopus 로고
    • High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
    • Cuisset, T. et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J. Thromb. Haemost. 4, 542-549 (2006).
    • (2006) J. Thromb. Haemost. , vol.4 , pp. 542-549
    • Cuisset, T.1
  • 38
    • 33750479499 scopus 로고    scopus 로고
    • Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
    • Hochholzer, W. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J. Am. Coll. Cardiol. 48, 1742-1750 (2006).
    • (2006) J. Am. Coll. Cardiol. , vol.48 , pp. 1742-1750
    • Hochholzer, W.1
  • 39
    • 33846837282 scopus 로고    scopus 로고
    • Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: Is the current antiplatelet therapy adequate?
    • Bliden, K. P. et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol. 49, 657-666 (2007).
    • (2007) J. Am. Coll. Cardiol. , vol.49 , pp. 657-666
    • Bliden, K.P.1
  • 40
    • 34250020766 scopus 로고    scopus 로고
    • Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
    • Buonamici, P. et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49, 2312-2317 (2007).
    • (2007) J. Am. Coll. Cardiol. , vol.49 , pp. 2312-2317
    • Buonamici, P.1
  • 41
    • 60949083948 scopus 로고    scopus 로고
    • Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
    • Sibbing, D. et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 53, 849-856 (2009).
    • (2009) J. Am. Coll. Cardiol. , vol.53 , pp. 849-856
    • Sibbing, D.1
  • 42
    • 59849120163 scopus 로고    scopus 로고
    • Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12-month follow-up
    • Marcucci, R. et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 11 9, 237-242 (2009).
    • (2009) Circulation , vol.11 , Issue.9 , pp. 237-242
    • Marcucci, R.1
  • 43
    • 34447636769 scopus 로고    scopus 로고
    • Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
    • Bonello, L. et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J. Thromb. Haemost. 5, 1630-1636 (2007).
    • (2007) J. Thromb. Haemost. , vol.5 , pp. 1630-1636
    • Bonello, L.1
  • 44
    • 41249093357 scopus 로고    scopus 로고
    • Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. A multicenter randomized prospective study
    • Bonello, L. et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. A multicenter randomized prospective study. J. Am. Coll. Cardiol. 51, 1404-1411 (2008).
    • (2008) J. Am. Coll. Cardiol. , vol.51 , pp. 1404-1411
    • Bonello, L.1
  • 45
    • 34047096264 scopus 로고    scopus 로고
    • Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives
    • Angiolillo, D. J. et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol. 49, 1505-1516 (2007).
    • (2007) J. Am. Coll. Cardiol. , vol.49 , pp. 1505-1516
    • Angiolillo, D.J.1
  • 46
    • 57649084454 scopus 로고    scopus 로고
    • Impact of "nuisance"bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation
    • Roy, P. et al. Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation. Am. J. Cardiol. 102, 1614-1617 (2008).
    • (2008) Am. J. Cardiol. , vol.102 , pp. 1614-1617
    • Roy, P.1
  • 47
    • 56849095254 scopus 로고    scopus 로고
    • Initiation and persistence with clopidogrel treatment after acute myocardial infarction: A nationwide study
    • Sorensen, R. et al. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Brit. J. Clin. Pharmacol. 66, 875-884 (2008).
    • (2008) Brit. J. Clin. Pharmacol. , vol.66 , pp. 875-884
    • Sorensen, R.1
  • 48
    • 38349065084 scopus 로고    scopus 로고
    • Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study
    • Gilard, M. et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 51, 256-260 (2008).
    • (2008) J. Am. Coll. Cardiol. , vol.51 , pp. 256-260
    • Gilard, M.1
  • 49
    • 61549124132 scopus 로고    scopus 로고
    • Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
    • Ho, P. M. et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301, 937-944 (2009).
    • (2009) JAMA , vol.301 , pp. 937-944
    • Ho, P.M.1
  • 50
    • 57149104093 scopus 로고    scopus 로고
    • Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel
    • Siller-Matula, J. M. et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am. Heart J. 157, 148.e1-148.e5 (2009).
    • (2009) Am. Heart J. , vol.157
    • Siller-Matula, J.M.1
  • 51
    • 64849087438 scopus 로고    scopus 로고
    • Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel
    • Sibbing, D. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb. Haemost. 101, 714-719 (2009).
    • (2009) Thromb. Haemost. , vol.101 , pp. 714-719
    • Sibbing, D.1
  • 52
    • 70249139788 scopus 로고    scopus 로고
    • Pharmacodynamic and clinical efficacy of clopidogrel and of prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials
    • O'Donoghue, M. L. et al. Pharmacodynamic and clinical efficacy of clopidogrel and of prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 374, 989-997 (2009).
    • (2009) Lancet , vol.374 , pp. 989-997
    • O'Donoghue, M.L.1
  • 53
    • 48449101872 scopus 로고    scopus 로고
    • The association of cigarette smoking with enhanced platelet inhibition by clopidogrel
    • Bliden, K. P. et al. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J. Am. Coll. Cardiol. 52, 531-533 (2008).
    • (2008) J. Am. Coll. Cardiol. , vol.52 , pp. 531-533
    • Bliden, K.P.1
  • 54
    • 63549115843 scopus 로고    scopus 로고
    • Interaction between cigarette smoking and clinical benefit of clopidogrel
    • Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P. & Sabatine, M. S. Interaction between cigarette smoking and clinical benefit of clopidogrel. J. Am. Coll. Cardiol. 53, 1273-1278 (2009).
    • (2009) J. Am. Coll. Cardiol. , vol.53 , pp. 1273-1278
    • Desai, N.R.1    Mega, J.L.2    Jiang, S.3    Cannon, C.P.4    Sabatine, M.S.5
  • 55
    • 58749094444 scopus 로고    scopus 로고
    • Cytochrome p-450 polymorphisms and response to clopidogrel
    • Mega, J. L. et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 354-362
    • Mega, J.L.1
  • 56
    • 58749090547 scopus 로고    scopus 로고
    • Genetic determinants of response to clopidogrel and cardiovascular events
    • Simon, T. et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360, 363-375 (2009).
    • (2009) N. Engl. J. Med. , vol.360 , pp. 363-375
    • Simon, T.1
  • 57
    • 58249135635 scopus 로고    scopus 로고
    • Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study
    • Collet, J. P. et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373, 309-317 (2009).
    • (2009) Lancet , vol.373 , pp. 309-317
    • Collet, J.P.1
  • 58
    • 33845528397 scopus 로고    scopus 로고
    • Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'
    • Michelson, A. D. et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J. Thromb. Haemost. 5, 75-81 (2007).
    • (2007) J. Thromb. Haemost. , vol.5 , pp. 75-81
    • Michelson, A.D.1
  • 59
    • 9644281092 scopus 로고    scopus 로고
    • Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting
    • Angiolillo, D. J. et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb. Res. 11 5, 101-108 (2005).
    • (2005) Thromb. Res. , vol.11 , Issue.5 , pp. 101-108
    • Angiolillo, D.J.1
  • 60
    • 7544239072 scopus 로고    scopus 로고
    • High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability
    • Angiolillo, D. J. et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 25, 1903-1910 (2004).
    • (2004) Eur. Heart J. , vol.25 , pp. 1903-1910
    • Angiolillo, D.J.1
  • 61
    • 9644281093 scopus 로고    scopus 로고
    • The difference between clopidogrel responsiveness and posttreatment platelet reactivity
    • Samara, W. M., Bliden, K. P., Tantry, U. S. & Gurbel, P. A. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. Thromb. Res. 11 5, 89-94 (2005).
    • (2005) Thromb. Res. , vol.11 , Issue.5 , pp. 89-94
    • Samara, W.M.1    Bliden, K.P.2    Tantry, U.S.3    Gurbel, P.A.4
  • 62
    • 0038649988 scopus 로고    scopus 로고
    • Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity
    • Gurbel, P. A., Bliden, K. P., Hiatt, B. L. & O'Connor, C. M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107, 2908-2913 (2003).
    • (2003) Circulation , vol.107 , pp. 2908-2913
    • Gurbel, P.A.1    Bliden, K.P.2    Hiatt, B.L.3    O'Connor, C.M.4
  • 63
    • 23644433510 scopus 로고    scopus 로고
    • Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
    • Angiolillo, D. J. et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54, 2430-2435 (2005).
    • (2005) Diabetes , vol.54 , pp. 2430-2435
    • Angiolillo, D.J.1
  • 64
    • 34347242071 scopus 로고    scopus 로고
    • Thrombosis and drug-eluting stents: An objective appraisal
    • Holmes, D. R. Jr et al. Thrombosis and drug-eluting stents: an objective appraisal. J. Am. Coll. Cardiol. 50,109-118 (2007).
    • (2007) J. Am. Coll. Cardiol. , vol.50 , pp. 109-118
    • Holmes Jr., D.R.1
  • 65
    • 36849074168 scopus 로고    scopus 로고
    • Prasugrel:a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile
    • Jakubowski, J. A., Winters, K. J., Naganuma, H. & Wallentin, L. Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovas Drug Rev. 25, 357-374 (2007).
    • (2007) Cardiovas Drug Rev. , vol.25 , pp. 357-374
    • Jakubowski, J.A.1    Winters, K.J.2    Naganuma, H.3    Wallentin, L.4
  • 66
    • 34250714831 scopus 로고    scopus 로고
    • The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite
    • Sugidachi, A. et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J. Thromb. Haemost. 5, 1545-1551(2007).
    • (2007) J. Thromb. Haemost. , vol.5 , pp. 1545-1551
    • Sugidachi, A.1
  • 67
    • 33845451677 scopus 로고    scopus 로고
    • A comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formation
    • Brandt, J. T. et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153, 66 (2007).
    • (2007) Am. Heart J. , vol.153 , pp. 66
    • Brandt, J.T.1
  • 68
    • 33646732608 scopus 로고    scopus 로고
    • Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
    • Jernberg, T. et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur. Heart J. 27, 1166-1173 (2006).
    • (2006) Eur. Heart J. , vol.27 , pp. 1166-1173
    • Jernberg, T.1
  • 69
    • 36348977461 scopus 로고    scopus 로고
    • Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
    • Payne, C. D. et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J. Cardiovasc. Pharmacol. 50, 555-562 (2007).
    • (2007) J. Cardiovasc. Pharmacol. , vol.50 , pp. 555-562
    • Payne, C.D.1
  • 70
    • 37349111065 scopus 로고    scopus 로고
    • Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial
    • Wiviott, S. D. et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 11 6, 2923-2932 (2007).
    • (2007) Circulation , vol.11 , Issue.6 , pp. 2923-2932
    • Wiviott, S.D.1
  • 71
    • 67651173161 scopus 로고    scopus 로고
    • Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 trial
    • Michelson, A. D. et al. Pharmacodynamic assessment of platelet inhibition by prasugrel versus clopidogrel in the TRITON-TIMI 38 trial. Eur. Heart, J. 30, 1753-1763 (2009).
    • (2009) Eur. Heart J. , vol.30 , pp. 1753-1763
    • Michelson, A.D.1
  • 72
    • 36148983750 scopus 로고    scopus 로고
    • Prasugrel versus clopidogrel in patients with acute coronary syndromes
    • Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
    • (2007) N. Engl. J. Med. , vol.357 , pp. 2001-2015
    • Wiviott, S.D.1
  • 73
    • 60649112469 scopus 로고    scopus 로고
    • Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial
    • Montalescot, G. et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373, 723-731 (2009).
    • (2009) Lancet , vol.373 , pp. 723-731
    • Montalescot, G.1
  • 74
    • 55949103494 scopus 로고    scopus 로고
    • Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38
    • Wiviott, S. D. et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 11 8, 1626-1636 (2008).
    • (2008) Circulation , vol.11 , Issue.8 , pp. 1626-1636
    • Wiviott, S.D.1
  • 75
    • 18044388905 scopus 로고    scopus 로고
    • Preclinical and clinical studies with selective reversible direct P2Y12 antagonists
    • van Giezen, J. J. & Humphries, R. G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31, 195-204 (2005).
    • (2005) Semin. Thromb. Hemost. , vol.31 , pp. 195-204
    • Van Giezen, J.J.1    Humphries, R.G.2
  • 76
    • 33646261670 scopus 로고    scopus 로고
    • Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin
    • Husted, S. et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27,1038-1047 (2006).
    • (2006) Eur. Heart J. , vol.27 , pp. 1038-1047
    • Husted, S.1
  • 77
    • 35548995394 scopus 로고    scopus 로고
    • Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial
    • erratum 50, 2196 2007
    • Cannon, C. P. et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 50,1844-1851 (2007); erratum 50, 2196 (2007).
    • (2007) J. Am. Coll. Cardiol. , vol.50 , pp. 1844-1851
    • Cannon, C.P.1
  • 78
    • 35548933800 scopus 로고    scopus 로고
    • Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
    • Storey, R. F. et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50,1852-1856 (2007).
    • (2007) J. Am. Coll. Cardiol. , vol.50 , pp. 1852-1856
    • Storey, R.F.1
  • 79
    • 70149101223 scopus 로고    scopus 로고
    • Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    • Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045-1057 (2009).
    • (2009) N. Engl. J. Med. , vol.361 , pp. 1045-1057
    • Wallentin, L.1
  • 80
    • 0035085132 scopus 로고    scopus 로고
    • Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes
    • Storey, R. F., Oldroyd, K. G. & Wilcox, R. G. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost. 85, 401-407 (2001).
    • (2001) Thromb. Haemost. , vol.85 , pp. 401-407
    • Storey, R.F.1    Oldroyd, K.G.2    Wilcox, R.G.3
  • 81
    • 33344464928 scopus 로고    scopus 로고
    • Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial
    • Greenbaum, A. B. et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo-and active-controlled trial. Am. Heart J. 151, 689 (2006).
    • (2006) Am. Heart J. , vol.151 , pp. 689
    • Greenbaum, A.B.1
  • 82
    • 47649127254 scopus 로고    scopus 로고
    • 12 inhibitor for IV and oral use
    • 12 inhibitor for IV and oral use. J. Am. Coll. Cardiol. 49 (suppl. 2), 326A (2007).
    • (2007) J. Am. Coll. Cardiol. , vol.49 , Issue.SUPPL.2
    • Gretler, D.D.1
  • 84
    • 43149088638 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Agah, R., Plow, E. F. & Topol, E. J. in Platelets 2nd edn (ed. Michelson, A. D.) 1145-1163 (Elsevier/Academic Press, San Diego, (2007).
    • (2007) Platelets , pp. 1145-1163
    • Agah, R.1    Plow, E.F.2    Topol, E.J.3
  • 85
    • 0016246099 scopus 로고
    • An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia
    • Nurden, A. T. & Caen, J. P. An abnormal platelet glycoprotein pattern in three cases of Glanzmann's thrombasthenia. Br. J. Haematol. 28, 253-260 (1974).
    • (1974) Br. J. Haematol. , vol.28 , pp. 253-260
    • Nurden, A.T.1    Caen, J.P.2
  • 86
    • 0030999134 scopus 로고    scopus 로고
    • Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
    • Coller, B. S. Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. J. Clin. Invest. 99, 1467-1471 (1997).
    • (1997) J. Clin. Invest. , vol.99 , pp. 1467-1471
    • Coller, B.S.1
  • 87
    • 0031041549 scopus 로고    scopus 로고
    • In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
    • Ammar, T., Scudder, L. E. & Coller, B. S. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 95, 614-617 (1997).
    • (1997) Circulation , vol.95 , pp. 614-617
    • Ammar, T.1    Scudder, L.E.2    Coller, B.S.3
  • 88
    • 0029914728 scopus 로고    scopus 로고
    • Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis"
    • Reverter, J. C. et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J. Clin. Invest. 98, 863-874 (1996).
    • (1996) J. Clin. Invest. , vol.98 , pp. 863-874
    • Reverter, J.C.1
  • 89
    • 0033828457 scopus 로고    scopus 로고
    • GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidyl serine expression in whole blood
    • Furman, M. I. et al. GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidyl serine expression in whole blood. Thromb. Haemost. 84, 492-498 (2000).
    • (2000) Thromb. Haemost. , vol.84 , pp. 492-498
    • Furman, M.I.1
  • 90
    • 0030870212 scopus 로고    scopus 로고
    • F Networking in the hemostatic system. Integrin alphaIIb beta3 binds prothrombin and influences its activation
    • Byzova, T. V. & Plow, E. F Networking in the hemostatic system. Integrin alphaIIb beta3 binds prothrombin and influences its activation. J. Biol. Chem. 272, 27183-27188 (1997).
    • (1997) J. Biol. Chem. , vol.272 , pp. 27183-27188
    • Byzova, T.V.1    Plow, E.2
  • 91
    • 41849101706 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa receptor inhibitors in 2008: Do they still have a role?
    • Mukherjee, D. & Roffi, M. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role? J. Interv. Cardiol. 21, 118-121 (2008).
    • (2008) J. Interv. Cardiol. , vol.21 , pp. 118-121
    • Mukherjee, D.1    Roffi, M.2
  • 92
    • 0035895332 scopus 로고    scopus 로고
    • Increased mortality with oral platelet glycoprotein IIb/ IIIa antagonists: A meta-analysis of phase III multicenter randomized trials
    • Chew, D. P., Bhatt, D. L, Sapp, S. & Topol, E. J. Increased mortality with oral platelet glycoprotein IIb/ IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 103, 201-206 (2001).
    • (2001) Circulation , vol.103 , pp. 201-206
    • Chew, D.P.1    Bhatt, D.L.2    Sapp, S.3    Topol, E.J.4
  • 93
    • 0025873010 scopus 로고
    • "Activate"integrin alpha IIb beta 3 (platelet GPIIb-IIIa)
    • Du, X. P. et al. Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa). Cell 65, 409-416 (1991).
    • (1991) Cell , vol.65 , pp. 409-416
    • Du, X.P.1    Ligands, E.2
  • 94
    • 38949130475 scopus 로고    scopus 로고
    • Application of high-throughput screening to identify a novel a-specific small-molecule inhibitor of aIIb|33-mediated platelet interaction with fibrinogen
    • Blue, R., Murcia, M., Karan, C, Jirouskova, M. & Coller, B. S. Application of high-throughput screening to identify a novel a-specific small-molecule inhibitor of aIIb|33-mediated platelet interaction with fibrinogen. Blood 111, 1248-1256 (2008).
    • (2008) Blood , vol.111 , pp. 1248-1256
    • Blue, R.1    Murcia, M.2    Karan, C.3    Jirouskova, M.4    Coller, B.S.5
  • 95
    • 59849117765 scopus 로고    scopus 로고
    • Antiaggregatory and proangiogenic effects of a novel recombinant human dual specificity anti-integrin antibody
    • Escher, R. et al. Antiaggregatory and proangiogenic effects of a novel recombinant human dual specificity anti-integrin antibody. J. Thromb. Haemost. 7, 460-469 (2009).
    • (2009) J. Thromb. Haemost. , vol.7 , pp. 460-469
    • Escher, R.1
  • 96
    • 34247402058 scopus 로고    scopus 로고
    • Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation
    • Stoll, P. et al. Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler. Thromb. Vasc. Biol. 27, 1206-1212 (2007).
    • (2007) Arterioscler. Thromb. Vasc. Biol. , vol.27 , pp. 1206-1212
    • Stoll, P.1
  • 97
    • 84884771147 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Eisert, W. G. in Platelets 2nd edn (ed. Michelson, A. D.) 1165-1179 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 1165-1179
    • Eisert, W.G.1
  • 98
    • 0030297319 scopus 로고    scopus 로고
    • European Stroke Prevention Study.2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
    • Diener, H. C. et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1-13 (1996).
    • (1996) J. Neurol. Sci. , vol.143 , pp. 1-13
    • Diener, H.C.1
  • 99
    • 33646596912 scopus 로고    scopus 로고
    • Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial
    • ESPRIT Study Group et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367, 1665-1673 (2006).
    • (2006) Lancet , vol.367 , pp. 1665-1673
    • Study Group, E.1
  • 100
    • 51449116270 scopus 로고    scopus 로고
    • Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
    • Sacco, R. L. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238-1251 (2008).
    • (2008) N. Engl. J. Med. , vol.359 , pp. 1238-1251
    • Sacco, R.L.1
  • 102
    • 44349138210 scopus 로고    scopus 로고
    • Systematic review and metaanalysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention
    • Biondi-Zoccai, G. G. et al. Systematic review and metaanalysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am. Heart J. 155,1081-1089 (2008).
    • (2008) Am. Heart J. , vol.155 , pp. 1081-1089
    • Biondi-Zoccai, G.G.1
  • 103
    • 34548633702 scopus 로고    scopus 로고
    • Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial)
    • Lee, S. W. et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARE-Long trial). Am. J. Cardiol. 100,1103-1108 (2007).
    • (2007) Am. J. Cardiol. , vol.100 , pp. 1103-1108
    • Lee, S.W.1
  • 104
    • 52449085759 scopus 로고    scopus 로고
    • A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study
    • Angiolillo, D. J. et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29, 2202-2211 (2008).
    • (2008) Eur. Heart J. , vol.29 , pp. 2202-2211
    • Angiolillo, D.J.1
  • 106
    • 61849180442 scopus 로고    scopus 로고
    • Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study
    • Becker, R. C. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 373, 919-928 (2009).
    • (2009) Lancet , vol.373 , pp. 919-928
    • Becker, R.C.1
  • 107
    • 36448941387 scopus 로고    scopus 로고
    • Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury
    • Matsuoka, T. et al. Inhibitory effect of E5555, an orally active thrombin receptor antagonist, on intimal hyperplasia following balloon injury. J. Am. Coll. Cardiol. 43, 68A (2004).
    • (2004) J. Am. Coll. Cardiol. , vol.43
    • Matsuoka, T.1
  • 109
    • 43049116482 scopus 로고    scopus 로고
    • A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex
    • Takayama, H. et al. A novel antiplatelet antibody therapy that induces cAMP-dependent endocytosis of the GPVI/Fc receptor gamma-chain complex. J. Clin. Invest. 11 8, 1785-1795 (2008).
    • (2008) J. Clin. Invest. , vol.11 , Issue.8 , pp. 1785-1795
    • Takayama, H.1
  • 110
    • 58849165421 scopus 로고    scopus 로고
    • Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus formation via an allosteric mechanism
    • Miller, M. W. et al. Small-molecule inhibitors of integrin α2β1 that prevent pathological thrombus formation via an allosteric mechanism. Proc. Natl Acad. Sci. USA 106, 719-724 (2009).
    • (2009) Proc. Natl Acad. Sci. USA , vol.106 , pp. 719-724
    • Miller, M.W.1
  • 111
    • 69249236278 scopus 로고    scopus 로고
    • 2A receptor improves coronary patency in an in vivo model of recurrent thrombosis
    • 2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. Circulation 116, II-206 (2007).
    • (2007) Circulation , vol.116
    • Przyklenk, K.1
  • 112
    • 0032951722 scopus 로고    scopus 로고
    • In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016
    • Wallace, J. L. et al. In vivo antithrombotic effects of a nitric oxide-releasing aspirin derivative, NCX-4016. Thromb. Res. 93, 43-50 (1999).
    • (1999) Thromb. Res. , vol.93 , pp. 43-50
    • Wallace, J.L.1
  • 113
    • 34247121053 scopus 로고    scopus 로고
    • Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG
    • Lorusso, R. et al. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. Int. J. Cardiol. 11 8, 164-169 (2007).
    • (2007) Int. J. Cardiol. , vol.11 , Issue.8 , pp. 164-169
    • Lorusso, R.1
  • 114
    • 54949095069 scopus 로고    scopus 로고
    • The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons
    • Fontayne, A. et al. The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons. Thromb. Haemost. 100, 670-677 (2008).
    • (2008) Thromb. Haemost. , vol.100 , pp. 670-677
    • Fontayne, A.1
  • 115
    • 12444303861 scopus 로고    scopus 로고
    • Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin
    • Falati, S. et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin. J. Exp Med. 197, 1585-1598 (2003).
    • (2003) J. Exp Med. , vol.197 , pp. 1585-1598
    • Falati, S.1
  • 116
    • 0033574172 scopus 로고    scopus 로고
    • Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model
    • Kumar, A. et al. Recombinant soluble form of PSGL-1 accelerates thrombolysis and prevents reocclusion in a porcine model. Circulation 99,1363-1369 (1999).
    • (1999) Circulation , vol.99 , pp. 1363-1369
    • Kumar, A.1
  • 117
    • 38749140235 scopus 로고    scopus 로고
    • Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7, 8, 9, 10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis
    • Bedard, P. W. et al. Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8, 9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis. J. Pharmacol. Exp. Ther. 324, 497-506 (2008).
    • (2008) J. Pharmacol. Exp. Ther. , vol.324 , pp. 497-506
    • Bedard, P.W.1
  • 118
    • 38949147126 scopus 로고    scopus 로고
    • Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation
    • Meier, T. R. et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation. Thromb. Haemost. 99, 343-351 (2008).
    • (2008) Thromb. Haemost. , vol.99 , pp. 343-351
    • Meier, T.R.1
  • 119
    • 0023543565 scopus 로고
    • Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism
    • of proaggregatory and antiaggregatory prostaglandins in hemostasis
    • Gresele, P. et al. of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. J. Clin. Invest. 80,1435-1445 (1987).
    • (1987) J. Clin. Invest. , vol.80 , pp. 1435-1445
    • Gresele, P.1
  • 120
    • 0025020113 scopus 로고
    • Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers
    • Fiddler, G. I. & Lumley, P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 81 (Suppl. 1), 78 (1990).
    • (1990) A Review. Circulation , vol.81 , Issue.SUPPL.1 , pp. 78
    • Fiddler, G.I.1    Lumley, P.2
  • 121
    • 6944234992 scopus 로고    scopus 로고
    • Antithrombotic effects of S18886, a novel orally active thromboxane A2 receptor antagonist
    • Osende, J. I., Shimbo, D., Fuster, V., Dubar, M. & Badimon, J. J. Antithrombotic effects of S18886, a novel orally active thromboxane A2 receptor antagonist. J. Thromb. Haemost. 2, 492-498 (2004).
    • (2004) J. Thromb. Haemost. , vol.2 , pp. 492-498
    • Osende, J.I.1    Shimbo, D.2    Fuster, V.3    Dubar, M.4    Badimon, J.J.5
  • 122
    • 0037414069 scopus 로고    scopus 로고
    • Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin
    • Belhassen, L., Pelle, G., Dubois-Rande, J. L. & Adnot, S. Improved endothelial function by the thromboxane A2 receptor antagonist S18886 in patients with coronary artery disease treated with aspirin. J. Am. Coll. Cardiol. 41, 1198-1204 (2003).
    • (2003) J. Am. Coll. Cardiol. , vol.41 , pp. 1198-1204
    • Belhassen, L.1    Pelle, G.2    Dubois-Rande, J.L.3    Adnot, S.4
  • 123
    • 25144437017 scopus 로고    scopus 로고
    • The specific thromboxane receptor antagonist S18886: Pharmacokinetic and pharmacodynamic studies
    • Gaussem, P. et al. The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. J. Thromb. Haemost. 3, 1437-1445 (2005).
    • (2005) J. Thromb. Haemost. , vol.3 , pp. 1437-1445
    • Gaussem, P.1
  • 124
    • 33845927424 scopus 로고    scopus 로고
    • Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle
    • Yoshida, M. et al. Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle. Pharmacology 79, 50-56 (2007).
    • (2007) Pharmacology , vol.79 , pp. 50-56
    • Yoshida, M.1
  • 125
    • 0344737009 scopus 로고    scopus 로고
    • The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPα isoform in transfected COS-7 cells
    • Qiao, N. et al. The thromboxane receptor antagonist PBT-3, a hepoxilin stable analog, selectively antagonizes the TPα isoform in transfected COS-7 cells. J. Pharmacol. Exp. Ther. 307, 1142-1147 (2003).
    • (2003) J. Pharmacol. Exp. Ther. , vol.307 , pp. 1142-1147
    • Qiao, N.1
  • 126
    • 0025203077 scopus 로고
    • Cardioprotective actions of the specific thromboxane receptor antagonist (+)-S145Na following coronary occlusion and reperfusion in the rat. Res
    • Tsao, P. S. & Lefer, A. M. Cardioprotective actions of the specific thromboxane receptor antagonist (+)-S145Na following coronary occlusion and reperfusion in the rat. Res. Commun. Chem. Pathol. Pharmacol. 70, 205-211 (1990).
    • (1990) Commun. Chem. Pathol. Pharmacol. , vol.70 , pp. 205-211
    • Tsao, P.S.1    Lefer, A.M.2
  • 127
    • 0042386436 scopus 로고    scopus 로고
    • Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion- induced hepatic microcirculatory dysfunction in mice
    • Ito, Y. et al. Effects of selective cyclooxygenase inhibitors on ischemia/reperfusion-induced hepatic microcirculatory dysfunction in mice. Eur. Sur. Res. 35, 408-416 (2003).
    • (2003) Eur. Sur. Res. , vol.35 , pp. 408-416
    • Ito, Y.1
  • 128
    • 0005556702 scopus 로고    scopus 로고
    • Augmented contraction of the human isolated coronary artery by sumatriptan: A possible role for endogenous thromboxane
    • Maassen, V. A. et al. Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane. Br. J. Pharmacol. 11 9, 855-862 (1996).
    • (1996) Br. J. Pharmacol. , vol.11 , Issue.9 , pp. 855-862
    • Maassen, V.A.1
  • 129
    • 0030611110 scopus 로고    scopus 로고
    • Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass
    • Brothers, T. E., Robison, J. G., Elliott, B. M., Boggs, J. M. & Halushka, P. V. Thromboxane A2 receptor density increases during chronic exposure to thromboxane A2 receptor antagonists after porcine carotid bypass. Cardiovasc. Surg. 5, 92-98 (1997).
    • (1997) Cardiovasc. Surg. , vol.5 , pp. 92-98
    • Brothers, T.E.1    Robison, J.G.2    Elliott, B.M.3    Boggs, J.M.4    Halushka, P.V.5
  • 130
    • 4944241267 scopus 로고    scopus 로고
    • Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: The DAVID study
    • Neri Serneri, G. G., Coccheri, S., Marubini, E. & Violi, F. Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics (DAVID) Study Group. Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. Eur. Heart J. 25,1845-1852 (2004).
    • (2004) Eur. Heart J , vol.25 , pp. 1845-1852
    • Neri Serneri, G.G.1    Coccheri, S.2    Marubini, E.3    Violi, F.4
  • 131
    • 12244289930 scopus 로고    scopus 로고
    • Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function
    • Dogne, J. M. et al. Pharmacological evaluation of the novel thromboxane modulator BM-567 (I/II). Effects of BM-567 on platelet function. Prostaglandins Leukot. Essent. Fatty Acids 68, 49-54 (2003).
    • (2003) Prostaglandins Leukot. Essent. Fatty Acids , vol.68 , pp. 49-54
    • Dogne, J.M.1
  • 132
    • 33644537934 scopus 로고    scopus 로고
    • Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion
    • Kolh, P. et al. Evaluation of BM-573, a novel TXA2 synthase inhibitor and receptor antagonist, in a porcine model of myocardial ischemia-reperfusion. Prostaglandins Other Lipid Mediat. 79, 53-73 (2006).
    • (2006) Prostaglandins Other Lipid Mediat , vol.79 , pp. 53-73
    • Kolh, P.1
  • 133
    • 0028851697 scopus 로고
    • Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid
    • Minuz, P. et al. Antiaggregating and vasodilatory effects of a new nitroderivative of acetylsalicylic acid. Thromb. Res. 80, 367-376 (1995).
    • (1995) Thromb. Res. , vol.80 , pp. 367-376
    • Minuz, P.1
  • 134
    • 65249093133 scopus 로고    scopus 로고
    • 2 are novel antiplatelet agents that do not prolong bleeding
    • 2 are novel antiplatelet agents that do not prolong bleeding. ACS Chem. Biol. 4, 115-126 (2009).
    • (2009) ACS Chem. Biol. , vol.4 , pp. 115-126
    • Singh, J.1
  • 135
    • 0036098158 scopus 로고    scopus 로고
    • Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αiIbβ3
    • Yap, C. L. et al. Essential role for phosphoinositide 3-kinase in shear-dependent signaling between platelet glycoprotein Ib/V/IX and integrin αIIbβ3. Blood 99,151-158 (2002).
    • (2002) Blood , vol.99 , pp. 151-158
    • Yap, C.L.1
  • 136
    • 44149087073 scopus 로고    scopus 로고
    • Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat
    • Sturgeon, S. A., Jones, C., Angus, J. A. & Wright, C. E. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat. Eur. J. Pharmacol. 587, 209-215 (2008).
    • (2008) Eur. J. Pharmacol. , vol.587 , pp. 209-215
    • Sturgeon, S.A.1    Jones, C.2    Angus, J.A.3    Wright, C.E.4
  • 137
    • 42949101432 scopus 로고    scopus 로고
    • Discovery-based strategies for studying platelet function
    • Flaumenhaft, R. & Dilks, J. R. Discovery-based strategies for studying platelet function. Mini Rev. Med. Chem. 8, 350-357 (2008).
    • (2008) Mini Rev. Med. Chem. , vol.8 , pp. 350-357
    • Flaumenhaft, R.1    Dilks, J.R.2
  • 138
    • 67651056213 scopus 로고    scopus 로고
    • Platelet membrane proteomics: A novel repository for functional research
    • Lewandrowski, U. et al. Platelet membrane proteomics: a novel repository for functional research. Blood 11 4, e10-e19 (2009).
    • (2009) Blood , vol.11 , Issue.4
    • Lewandrowski, U.1
  • 139
    • 58249142988 scopus 로고    scopus 로고
    • Methods for the measurement of platelet function
    • Michelson, A. D. Methods for the measurement of platelet function. Am. J. Cardiol. 103 (suppl. 3), 20A-6A (2009).
    • (2009) Am. J. Cardiol. , vol.103 , Issue.SUPPL. 3
    • Michelson, A.D.1
  • 140
    • 84884782037 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Steinhubl, S. R. in Platelets 2nd edn (ed. Michelson, A. D.) 509-518 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 509-518
    • Steinhubl, S.R.1
  • 141
    • 18244414272 scopus 로고    scopus 로고
    • Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists
    • Michelson, A. D. et al. Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101, 1013-1018 (2000).
    • (2000) Circulation , vol.101 , pp. 1013-1018
    • Michelson, A.D.1
  • 142
    • 36348943475 scopus 로고    scopus 로고
    • Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
    • Brandt, J. T. et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5, 2429-2436 (2007).
    • (2007) J. Thromb. Haemost. , vol.5 , pp. 2429-2436
    • Brandt, J.T.1
  • 143
    • 66349133650 scopus 로고    scopus 로고
    • Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
    • Mega, J. L. et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 11 9, 2553-2560 (2009).
    • (2009) Circulation , vol.11 , Issue.9 , pp. 2553-2560
    • Mega, J.L.1
  • 144
    • 58149476444 scopus 로고    scopus 로고
    • Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis
    • Bonello, L. et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103, 5-10 (2009).
    • (2009) Am. J. Cardiol. , vol.103 , pp. 5-10
    • Bonello, L.1
  • 145
    • 57549099501 scopus 로고    scopus 로고
    • Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders
    • Cuisset, T. et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders. J. Am. Coll. Cardiol. Cardiovasc. Inter. 1, 649-653 (2008).
    • (2008) J. Am. Coll. Cardiol. Cardiovasc. Inter. , vol.1 , pp. 649-653
    • Cuisset, T.1
  • 146
    • 67650745975 scopus 로고    scopus 로고
    • Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/ or resistance to clopidogrel study
    • Valgimigli, M. et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention. Results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/ or resistance to clopidogrel study. Circulation 11 9, 3215-3222 (2009).
    • (2009) Circulation , vol.11 , Issue.9 , pp. 3215-3222
    • Valgimigli, M.1
  • 147
    • 84884800657 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/Academic Press, San Diego
    • Andrews, R. K., Berndt, M. C. & Lopez, J. A. in Platelets 2nd edn (ed. Michelson, A. D.) 145-163 (Elsevier/Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 145-163
    • Andrews, R.K.1    Berndt, M.C.2    Lopez, J.A.3
  • 148
    • 73149093011 scopus 로고    scopus 로고
    • 2nd edn (ed. Michelson, A. D.) Elsevier/ Academic Press, San Diego
    • Plow, E. F., Pesho, M. M. & Ma, Y. Q. in Platelets 2nd edn (ed. Michelson, A. D.) 165-178 (Elsevier/ Academic Press, San Diego, 2007).
    • (2007) Platelets , pp. 165-178
    • Plow, E.F.1    Pesho, M.M.2    Ma, Y.Q.3
  • 150
  • 151
    • 50449098285 scopus 로고    scopus 로고
    • Mechanisms of thrombus formation
    • Furie, B. & Furie, B. C. Mechanisms of thrombus formation. N. Engl. J. Med. 359, 938-949 (2008).
    • (2008) N. Engl. J. Med. , vol.359 , pp. 938-949
    • Furie, B.1    Furie, B.C.2
  • 152
    • 34547760330 scopus 로고    scopus 로고
    • A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
    • Lordkipanidze, M. et al. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur. Heart J. 28,1702-1708 (2007).
    • (2007) Eur. Heart J. , vol.28 , pp. 1702-1708
    • Lordkipanidze, M.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.